Clinical Scorecard: FDA approves combo for ESR1-mutated breast cancer
At a Glance
| Category | Detail |
|---|---|
| Condition | Estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer |
| Key Mechanisms | Combination of imlunestrant and abemaciclib targeting ESR1 mutations |
| Target Population | Adults with disease progression following at least 1 line of endocrine therapy |
| Care Setting | Oncology clinical practice |
Key Highlights
- FDA approved imlunestrant with abemaciclib for specific breast cancer patients
- Guardant360 CDx assay authorized for detecting ESR1 mutations
- Study included 874 adults with previously treated advanced breast cancer
- Significant improvement in progression-free survival with combination therapy
- Warnings for embryo-fetal toxicity associated with both drugs
Guideline-Based Recommendations
Diagnosis
- Use Guardant360 CDx assay to detect ESR1 mutations
Management
- Consider imlunestrant plus abemaciclib for patients with ESR1 mutations
Monitoring & Follow-up
- Monitor for progression-free survival and response rates
Risks
- Embryo-fetal toxicity, diarrhea, neutropenia, interstitial lung disease, hepatotoxicity, venous thromboembolism
Patient & Prescribing Data
Adults with ESR1-mutated advanced or metastatic breast cancer
Combination therapy shows improved progression-free survival in patients with ESR1 mutations
Clinical Best Practices
- Utilize genetic testing for ESR1 mutations in treatment planning
- Monitor patients for adverse effects associated with imlunestrant and abemaciclib
Related Resources & Content
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.
